Clinical

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.

Genmab’s epcoritamab (Epkinly) streamlines bispecific antibody workflows for DLBCL and follicular lymphoma, cutting chair time, waste, and costs.

In a cohort of veterans with steatotic liver disease, patients with metabolic- and alcohol-associated liver disease had the lowest incidence of cirrhosis.

Meta-analysis links obstructive sleep apnea to early kidney injury markers, especially in severe OSA and hypertension, highlighting need for renal monitoring.

Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks transparency, which may lower uptake.

Enfortumab vedotin plus pembrolizumab boosts survival and pCR in muscle-invasive bladder cancer, according to EV-304 trial data.

Azathioprine use in organ transplant recipients increases the risk of squamous cell, but not basal cell, carcinoma.

Experts examine evolving long COVID definitions, risk factors, diagnosis challenges, vaccine impact, and workforce effects.

This approval was based on data from the Beamion LUNG-1 trial.

Emerging CRC diagnostic tools along with better public awareness could help reverse rising deaths in younger adults, says Jordan Karlitz, MD.

Orforglipron achieved greater A1C reduction and weight loss than oral semaglutide, highlighting its potential as a needle-free option for type 2 diabetes.

Nurse understaffing linked to higher in-hospital mortality, 30-day readmissions, and longer stays.

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

FDA draft guidance outlines a new pathway to speed up approval of individualized genome and RNA therapies for rare diseases when RCTs are not feasible.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Kavita Nair, PhD, discusses how clinicians select MS therapies, the role of cost and access, and why policy changes could threaten patient outcomes.

With radiopharmaceutical therapy use up 20 times in Medicare, experts analyze clinical pathways for delivering it in academic and community settings.

Higher local recurrence growth rates and high-grade tumors were linked to increased disease-specific death after resection.

A review article examines questions about sequencing treatments in light of recent developments in relapsed/refractory mantle cell lymphoma.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants.